Advanced Oncotherapy PLC's (LON:AVO) Jonathan Farr, Chief Clinical Officer, talks to Proactive London's Katie Pilbeam about their latest findings in regard to resistant cancers.
The firm recently announced to their investors that it had demonstrated superiority of its LIGHT technology in 'biologically enhanced particle therapy' to treat these resistant cancers.
Farr explains, these cancers are responsible for most relapses and one of the major causes of death in cancer.
Due to the their LIGHT system and its smaller beam size compared to legacy systems and its ability to deposit a greater level of radiation damage in a micro-target volume, it is suited to contribute to the development of personalised medicines.